| Obesity |
1 |
1 |
| Contraception |
0 |
0.38 |
| Insurance |
0 |
0.34 |
| Metabolism |
0 |
0.34 |
| Weight Loss |
0 |
0.34 |
| GLP-1 Receptor Agonist |
0 |
0.29 |
| Sterilization, Birth Control |
0 |
0.24 |
| Acute Coronary Syndrome |
0 |
0.18 |
| Adverse Effects |
0 |
0.17 |
| Alcohol Use |
0 |
0.17 |
| Birth |
0 |
0.17 |
| Cardiovascular disease |
0 |
0.17 |
| Clinical Research |
0 |
0.17 |
| Endocrinology |
0 |
0.17 |
| Epidemic |
0 |
0.17 |
| Estrogen |
0 |
0.17 |
| Family Planning |
0 |
0.17 |
| Fertility |
0 |
0.17 |
| Food and Drug Administration (FDA) |
0 |
0.17 |
| Gastroparesis |
0 |
0.17 |
| Infarction |
0 |
0.17 |
| Iris |
0 |
0.17 |
| Liver |
0 |
0.17 |
| Meta-Analysis |
0 |
0.17 |
| New York |
0 |
0.17 |
| Nonalcoholic Steatohepatitis |
0 |
0.17 |
| Progestin |
0 |
0.17 |
| Receptors |
0 |
0.17 |
| Revenue and Practice Management |
0 |
0.17 |
| Shared Decision-Making |
0 |
0.17 |
| Type 2 Diabetes Mellitus |
0 |
0.99 |
| Unstable Angina |
0 |
0.17 |
| Weight Management |
0 |
0.17 |
| Angina Pectoris |
0 |
0.14 |
| Gastroesophageal Reflux Disease |
0 |
0.14 |
| Non-Alcoholic Fatty Liver Disease |
0 |
0.14 |
| Pregnancy |
0 |
0.14 |
| Abdominal Infection |
0 |
0.09 |
| Cardiovascular Risk Management |
0 |
0.09 |
| Cerebrovascular Accident |
0 |
0.09 |
| Healthcare and Medical Technology |
0 |
0.09 |
| Myocardial Infarction (MI) |
0 |
0.09 |
| Pancreatitis |
0 |
0.09 |
| Patient Safety |
0 |
0.09 |